•  
  •  
 

Abstract

Bempedoic acid is a newly discovered a novel lipid-lowering non-statin agent used for the management of dyslipidemiaand the reduction of cardiovascular risk. Its therapeutic mechanism of action is mediated by the inactivation of upstream enzymatic activity of adenosine triphosphate-citrate lyase (ATP -citrate lyase) that implicated in the cholesterol biosynthetic pathway. Clinical studies have reported that the treatment with bempedoic acid alone may reduce LDL-C levels via nearly 20% when compared with placebo, and by up to 38% when administered in combination with ezetimibe. This new drug has showed a satisfactory safety and tolerability profile demonstrated by a minimal level of muscle-related side effects but accompanied by modest elevation of gout risk. This review provides an overview of the mechanism of action, pharmacokinetic characteristics, clinical performance, and safety profile of bempedoic acid, pointing its growing importance in controlling of dyslipidemia and reduction cardiovascular risk.

References

1] Pappan N, Awosika AO, Rehman A. Dyslipidemia [Updated 2024 Mar 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https:// www.ncbi.nlm.nih.gov/books/NBK560891/.

[2] Ghazwani M, Mahmood SE, Gosadi IM, Bahri AA, Ghazwani SH, Khmees RA. Prevalence of dyslipidemia and its determinants among the adult population of the Jazan region. Int J Gen Med 2023;16:4215—26. https://doi.org/ 10.2147/IJGM.S429462.

[3] Expert Market Research. Dyslipidemia epidemiology forecast 2025-2034. 2025. Available from: https://www. expertmarketresearch.com/reports/dyslipidemia- epidemiology-forecast.

[4] Ballena-Caicedo J, Zuzunaga-Montoya FE, Loayza- Castro JA, Vasquez-Romero LEM, Tapia-Limonchi R, De Carrillo CIG, et al. Global prevalence of dyslipidemias in the general adult population: a systematic review and meta- analysis. J Health Popul Nutr 2025 Aug 26;44(1):308. https:// doi.org/10.1186/s41043-025-01054-3.

[5] de Oliveira LLH, de Assis ACR, Giraldez VZR, Scudeler TL, Soares PR. Dyslipidemia: a narrative review on pharmaco therapy. Pharmaceuticals (Basel) 2024 Feb 23;17(3):289. https://doi.org/10.3390/ph17030289.

[6] Muscoli S, Ifrim M, Russo M, Candido F, Sanseviero A, Milite M, et al. Current options and future perspectives in the treatment of dyslipidemia. J Clin Med 2022 Aug 12; 11(16):4716. https://doi.org/10.3390/jcm11164716.

[7] Bays HE. Cholesterol absorption inhibitors (Ezetimibe) and bile acid-binding resins (Colesevelam HCl) as therapy for dyslipidemia in patients with diabetes mellitus. In: Jenkins AJ, Toth PP, editors. Lipoproteins in diabetes mel litus. Contemporary diabetes. Cham: Humana; 2023. https:// doi.org/10.1007/978-3-031-26681-2_26.

[8] Wichaiyo S, Supharattanasitthi W. Bempedoic acid: a new non-statin drug for the treatment of dyslipidemia. Clin Drug Invest 2021 Oct;41(10):843—51. https://doi.org/10.1007/ s40261-021-01075-w.

[9] De Filippo O, D'Ascenzo F, Iannaccone M, Bertaina M, Leone A, Borzillo I, et al. Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials. Cardiovasc Diabetol 2023 Nov 28;22(1):324. https://doi.org/10.1186/s12933-023-02022-z.

[10] Biolo G, Vinci P, Mangogna A, Landolfo M, Schincariol P, Fiotti N, et al. Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome. Front Cardiovasc Med 2022 Oct 28;9:1028355. https:// doi.org/10.3389/fcvm.2022.

[11] Drexel H, Mader A. Bempedoic acid: how will it shape the future lipid-lowering landscape? mode of action, evidence, and clinical use. Cardiology 2024;149(1):71—7. https:// doi.org/10.1159/000535372.

[12] Ruscica M, Sirtori CR, Carugo S, Banach M, Corsini A. Bempedoic acid: for whom and when. Curr Atheroscler Rep 2022 Oct;24(10):791—801. https://doi.org/10.1007/s11883-022- 01054-2.

[13] Dai L, Zuo Y, You Q, Zeng H, Cao S. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol 2021 Jul 23;28(8):825—33. https://doi.org/10.1177/2047487320930585.

[14] Riesen WF. Bempedoic acid: a new player in lipid-lowering. J Cardiovasc Med Cardiol 2024;11(2):22—3. https://doi.org/ 10.17352/2455-2976.000205.

[15] Sharif MH, Orakzai AA, Khaleeque M, Raza SA, Khan OS, Jan MH, et al. Efficacy and safety of bempedoic acid as a treatment option for hyperlipidemia: a systematic review. MA'AEN JOURNAL FOR MEDICAL SCIENCES 2026;5:1—10 9 Adv Clinic Med Res Healthcare Deliv 2024;4:1—8. https:// doi.org/10.53785/2769-2779.1198.

[16] Nisar S, Sohail S, Fatima S, Akhtar MT, Ahmad M, Hanif MW, et al. Efficacy and safety of bempedoic acid in patients with hyperlipidemia and non-alcoholic fatty liver disease. J Commun Hosp Intern Med Perspect 2024 Mar 4; 14(2):40—8. https://doi.org/10.55729/2000-9666.1313.

[17] Reddy S, Deoker A. Effects of bempedoic acid on markers of inflammation and Lp(a). Curr Opin Cardiol 2024 Jul 1;39(4): 280—5. https://doi.org/10.1097/HCO.0000000000001137.

[18] Afzal MA, Khalid N, Abdullah M, Haiy AU, Hassan MA, Sana H, et al. The latest evidence on bempedoic acid: meta- analysis of safety and efficacy in high cardiovascular risk patients with hypercholesterolemia. J Commun Hosp Intern Med Perspect 2024 Mar 4;14(2):12—22. https://doi.org/ 10.55729/2000-9666.1305.

[19] Li Y, Gao H, Zhao J, Ma L, Hu D. Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: a meta-analysis and a systematic randomized controlled trial review. PLoS One 2024 Jan 26;19(1):e0297854. https://doi.org/10.1371/journal.pone.0297854.

[20] Yarrarapu SNS, Goyal A, Venkata VS, Panchal V, Sivasubramanian BP, Du DT, et al. Comprehensive review of statin-intolerance and the practical application of Bem pedoic Acid. J Cardiol 2024 Jul;84(1):22—9. https://doi.org/ 10.1016/j.jjcc.2024.03.006.

[21] Di Fusco SA, Aquilani S, Spinelli A, Alonzo A, Castello L, Caldarola P, et al. ANMCO expert opinion: posizionamento terapeutico dell’acido bempedoico nel trattamento dell’i percolesterolemia (ANMCO expert opinion: bempedoic acid place in therapy for hypercholesterolemia manage ment). G Ital Cardiol (Rome) 2023 Jun;24(6):490—8. https:// doi.org/10.1714/4041.40210. Italian.

[22] Agnello F, Ingala S, Laterra G, Scalia L, Barbanti M. Novel and emerging LDL-C lowering strategies: a new era of dyslipidemia management. J Clin Med 2024 Feb 22;13(5): 1251. https://doi.org/10.3390/jcm13051251.

[23] Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc 2019;8(7):e011662. https://doi.org/10.1161/ JAHA.118.011662.

[24] Dymala K. Cardiovascular outcomes in patients intolerant to statins treated with bempedoic acid. Contemp Clinic 2024 Feb 5. Available from: https://www.contemporaryclinic. com/news/cardiovascular-outcomes-in-patients-intolerant- to-statins-treated-with-bempedoic-acid.

[25] Pirillo A, Norata GD, Catapano AL. LDL-Cholesterol- Lowering therapy. 2020 Apr 30. In: von Eckardstein A, Binder CJ, editors. Prevention and treatment of atheroscle rosis: improving state-of-the-art management and search for novel targets [Internet]. Cham (CH): Springer; 2022.

[26] Amore BM, MacDougall DE, Hanselman JC, Emery MG. Phase 1, Single- and multiple-ascending-dose, food-effect, and East Asian subject studies to assess the pharmacoki netics, safety, and tolerability of bempedoic acid, a selective inhibitor of adenosine triphosphate citrate lyase. Clin Pharmacol Drug Dev 2023 Oct;12(10):1022—35. https:// doi.org/10.1002/cpdd.1297.

[27] Amore BM, Cramer C, MacDougall D, Emery MG. The disposition and metabolism of bempedoic acid, a potent inhibitor of ATP citrate lyase, in healthy human subjects. Drug Metab Dispos 2023 May;51(5):599—609. https://doi.org/ 10.1124/dmd.122.001142.

[28] Jadhav SB, Amore BM, Bockbrader H, Crass RL, Chapel S, Sasiela WJ, et al. Population pharmacokinetic and phar macokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia. J Pharmacokinet Pharmacodyn 2023 Oct;50(5):351—64. https://doi.org/ 10.1007/s10928-023-09864-w.

[29] Amore BM, Sasiela WJ, Ries DK, Tresh P, Emery MG. Pharmacokinetics of bempedoic acid in patients with renal impairment. Clin Transl Sci 2022 Mar;15(3):789—98. https:// doi.org/10.1111/cts.13202. [30] Amore BM, Patel N, Batheja P, Templeton IE, Jones HM, Louie MJ, et al. Physiologically based pharmacokinetic model development and verification for bioequivalence testing of bempedoic acid oral suspension and reference tablet formulation. Pharmaceutics 2023;15(5):1476. https:// doi.org/10.3390/pharmaceutics15051476.

[31] Duell PB, Banach M, Catapano AL, Laufs U, Mancini GBJ, Ray KK, et al. Efficacy and safety of bempedoic acid in pa tients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials. J Clin Lipidol 2024 Mar-Apr;18(2):e153—65. https:// doi.org/10.1016/j.jacl.2023.12.005.

[32] Lincoff AM, Ray KK, Sasiela WJ, Haddad T, Nicholls SJ, Li N, et al. Comparative cardiovascular benefits of bempe doic acid and Statin drugs. J Am Coll Cardiol 2024 Jul 9; 84(2):152—62. https://doi.org/10.1016/j.jacc.2024.04.048.

33] Ray KK, Nicholls SJ, Li N, Louie MJ, Brennan D, Lincoff AM, et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR outcomes randomised trial. Lancet Diabetes Endo crinol 2024 Jan;12(1):19—28. https://doi.org/10.1016/S2213- 8587(23)00316-9.

[34] Abrahams T, Nelson AJ, Nicholls SJ. How will our practice change after the CLEAR outcomes trial? Curr Atheroscler Rep 2024 Mar;26(3):83—9. https://doi.org/10.1007/s11883- 024-01188-5.

[35] Walter K. Bempedoic acid could lower LDL-cholesterol significantly. HCPLive [Internet] 2020 Nov 18 [cited 2025 Sep 14]. Available from: https://www.hcplive.com/view/ bempedoic-acid-ldl-cholesterol.

[36] Del Carpio-Tenorio C, Llerena-Velastegui J, Villacis- Lopez C, Placencia-Silva M, Santander-Fuentes C, Benitez- Acosta K, et al. Impact of Bempedoic acid on LDL-C reduction and cardiovascular outcomes: a comprehensive meta-analysis of randomized controlled trials. Curr Probl Cardiol 2024 Feb;49(2):102191. https://doi.org/10.1016/ j.cpcardiol.2023.102191.

[37] Goyal A, Changez MIK, Tariq MD, Mushtaq F, Shamim U, Sohail AH, et al. Efficacy and outcomes of Bempedoic acid versus placebo in patients with statin-intolerance: a pilot systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol 2024 Feb;49(2):102236. https://doi.org/10.1016/j.cpcardiol.2023.102236.

[38] Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019 Mar 14;380(11): 1022—32. https://doi.org/10.1056/NEJMoa1803917.

[39] Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low- density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA 2019 Nov 12;322(18):1780—8. https:// doi.org/10.1001/jama.2019.16585. Erratum in: JAMA. 2020 Jan 21;323(3):282, https://doi.org/10.1001/jama.2019.20661.

[40] Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed- dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 2020;27(6):593—603. https:// doi.org/10.1177/2047487319864671.

[41] Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular out comes in statin-intolerant patients. N Engl J Med 2023 Apr 13; 388(15):1353—64. https://doi.org/10.1056/NEJMoa2215024.

[42] Suresh A, Balakrishnan A, Ramaswamy V, Natesan S. Analytical method development and validation for simul taneous estimation of Bempedoic acid and Ezetimibe in pure and its pharmaceutical dosage form by RP-HPLC. Biomed Chromatogr 2024 Jun;26:e5938. https://doi.org/ 10.1002/bmc.5938. 10 MA'AEN JOURNAL FOR MEDICAL SCIENCES 2026;5:1—10

[43] McQueen RB, Baum SJ, Louie MJ, Sasiela WJ, Bilitou A, Shah H, et al. Potential cardiovascular events avoided with bempedoic acid plus ezetimibe fixed-dose combination compared with ezetimibe alone in patients with athero sclerotic cardiovascular disease taking maximally tolerated statins. Am J Cardiovasc Drugs 2023 Jan;23(1):67—76. https:// doi.org/10.1007/s40256-022-00552-7.

[44] Seijas-Amigo J, Cordero A, Olmo RF, Cortez Quiroga GA, Facila L, Salgado-Barreira  A, et al. Patients with high car diovascular risk as candidates to bempedoic acid, after treatment with statins, ezetimibe and PCSK9 inhibitors: an estimation and cost-effectiveness analysis. J Cardiovasc Pharmacol 2023 Jan 1;81(1):70—5. https://doi.org/10.1097/ FJC.0000000000001365.

[45] Dandamudi S, Rangapuram V. Synchronized analysis of bempedoic acid and ezetimibe in pure binary mixture and their combined tablets by a new stability indicating RP- UPLC metho. Int J Health Sci 2022 May;6(S3):7278—90. https://doi.org/10.53730/ijhs.v6nS3.7743.

[46] Ridker PM, Lei L, Ray KK, Ballantyne CM, Bradwin G, Rifai N. Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: a secondary analysis of the CLEAR harmony trial. J Clin Lipidol 2023 Mar-Apr;17(2):297—302. https://doi.org/ 10.1016/j.jacl.2023.02.002.

[47] Marazzi G, Caminiti G, Perrone MA, Campolongo G, Cacciotti L, Giamundo DM, et al. Addition of bempedoic acid to statin—ezetimibe versus statin titration in patients with high cardiovascular risk: a single-centre prospective study. J Cardiovasc Dev Dis 2024;11(9):286. https://doi.org/ 10.3390/jcdd11090286.

[48] Toth P, Bray S, Worth GM. Relative efficacy of alirocumab, bempedoic acid, evolocumab, ezetimibe, and inclisiran added to statins for reduction of low density lipoprotein cholesterol - a network meta-analysis of randomized clinical trials. Circulation 2020 Nov 17;142(Suppl 3):13503. https:// doi.org/10.1161/CIRC.142.SUPPL_3.13503.

[49] Nicholls SJ, Ray KK, Lincoff AM, Sarnes E, Gillard KK, Bloedon L, et al. Cost-effectiveness of bempedoic acid in high cardiovascular risk patients with statin intolerance: an anal ysis of the CLEAR outcomes trial. Am J Cardiovasc Drugs 2025 Aug 20. https://doi.org/10.1007/s40256-025-00753-w.

[50] Morton JI, Liew D, Watts GF, Zoungas S, Nicholls SJ, Dixon P, et al. Rethinking cardiovascular prevention: cost- effective cholesterol lowering for statin-intolerant patients in Australia and the UK. Eur J Prev Cardiol 2025 Feb;26: zwaf114. https://doi.org/10.1093/eurjpc/zwaf114.

[51] Ray KK, Bloedon L, Li N, Nissen SE, co-authors. Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation - authors' reply. Lancet Diabetes Endocrinol 2024 Apr;12(4):228—9. https://doi.org/10.1016/ S2213-8587(24)00063-9.

[52] Yasmin F, Najeeb H, Moeed A, Ali E, Rahman SUU, Khan MS, et al. Abstract 18261: efficacy and safety of bem pedoic acid for prevention of cardiovascular events and diabetes mellitus: a systematic review and meta-analysis of randomized control trials. Circulation 2023. https://doi.org/ 10.1161/circ.148.suppl_1.18261.

[53] Giordano S, Spaccarotella CAM, Esposito G, Indolfi C. Bempedoic acid: a new player for statin-intolerant patients and beyond. Curr Opin Endocrinol Diabetes Obes 2024 Apr 1;31(2):90—7. https://doi.org/10.1097/MED.0000000000000853.

[54] Rajendran Y, Nandhakumar M, Eerike M, Kondampati N, Mali K, Chalissery LF, et al. A comparative analysis of low- density lipoprotein cholesterol (LDL-C)-Lowering activities of bempedoic acid, inclisiran, and PCSK9 inhibitors: a sys tematic review. Cureus 2024 Sep 22;16(9):e69900. https:// doi.org/10.7759/cureus.69900.

55] Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin ther apy after acute coronary syndromes. N Engl J Med 2015; 372(25):2387—97. https://doi.org/10.1056/NEJMoa1410489. [56] Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American col lege of cardiology/american heart association task force on practice guidelines. Circulation 2014;129(25_suppl_2):S1—45. https://doi.org/10.1161/01.cir.0000437738.63853.7a.

[57] Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/american heart association task force on clinical practice guidelines. Circulation 2019 Jun 18;139(25): e1082—143. https://doi.org/10.1161/CIR.0000000000000625. Epub 2018 Nov 10. Erratum in: Circulation. 2019 Jun 18;139(25): e1182-e1186, https://doi.org/10.1161/CIR.0000000000000698. Erratum in: Circulation. 2023 Aug 15;148(7):e5, https://doi.org/ 10.1161/CIR.0000000000001172.

[58] Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017 May 4;376(18):1713—22. https://doi.org/10.1056/ NEJMoa1615664.

[59] Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372(16):1489—99. https://doi.org/10.1056/NEJMoa1501 031.

[60] Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382(16): 1507—19. https://doi.org/10.1056/NEJMoa1912387.

Download

Share

COinS